On the pharmacogenetics of non-small cell lung cancer treatment
Open Access
- 17 February 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 12 (3) , 307-317
Abstract
Introduction. Despite many clinical efforts, non-small-cell lung cancer (NSCLC) has a dismal 5-year survival rate of 16%, and high incidence of recurrence. The success of biologically targeted agen...Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (Start-Up)
- ZonMw (Veni Grant)
This publication has 92 references indexed in Scilit:
- Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapyOncology Letters, 2013
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Cigarette smoking increases copy number alterations in nonsmall-cell lung cancerProceedings of the National Academy of Sciences, 2011
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancerBritish Journal of Cancer, 2011
- Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based ChemotherapyJNCI: Journal of the National Cancer Institute, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinibBritish Journal of Cancer, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitorsBritish Journal of Cancer, 2008